Introduction {#s1}
============

Epigenetic modifications are associated with genome stability, gene transcription, and metabolic regulation. Acetylation is one of the most characterized histone modifications. Histone acetyltransferase (HAT) and histone deacetylase (HDAC) enzymes control the levels of histone acetylation, modulating gene expression ([@B8]).

Sirtuins (SIRT) 1--7 are enzymes classified as class III HDACs. They exhibit different subcellular localizations: SIRT1, SIRT6, and SIRT7 are nuclear (although SIRT1 isoforms were also identified in the cytoplasm); SIRT2 is mainly cytosolic; SIRT3, SIRT4, and SIRT5 are mitochondrial and can shuttle to the nucleus ([@B9]).

The enzymatic activity of SIRTs is dependent on NAD^+^ as a cofactor and plays an important role in controlling gene expression, DNA repair, metabolism, oxidative stress response, mitochondrial function, and biogenesis. Deregulation of their activity may lead to tissue-specific degenerative events that underlie several human pathologies, including cancer, diabetes, and cardiovascular diseases ([@B34]; [@B70]; [@B95]). The most studied member of this enzymatic class is SIRT1. SIRT1 regulates metabolic pathways, cell survival, cellular senescence, and inflammation, and acts in the pathogenesis of chronic conditions such as diabetes as well as pulmonary, neurodegenerative, and cardiovascular diseases. Indeed, SIRT1 has been reported to play a key role in tumorigenesis, as an oncogene or tumor suppressor depending on the context specificity ([@B4]). It is able to control these processes *via* deacetylation of lysine groups of histone and non-histone proteins, including known transcription factors (FOXO, MyoD, p53, PGC-1α) ([@B52]).

Chronic inflammation caused by oxidative damage increases the risk of many chronic disorders, including heart, cardiovascular, and neurodegenerative diseases, obesity, insulin resistance, and type 2 diabetes (T2D) ([@B28]). Oxidative stress plays a key role in the pathogenesis of these conditions. The overproduction of reactive oxygen species (ROS), including free radicals, and reactive nitrogen species (RNS) can lead to damage of cellular components, such as lipids, proteins, and DNA. The imbalance between oxidants and antioxidants can result in cellular dysfunction, apoptosis, and necrosis ([@B59]).

SIRT1 guards against oxidative stress by activating gene transcription of PGC-1α *via* deacetylation, and by regulating transcription of factors such as the nuclear receptor peroxisome proliferator-activated receptor (PPAR), nuclear respiratory factor (NRF), and mitochondrial transcription factor A (TFAM), involved in modulation of biogenesis and mitochondrial function ([@B76]), and metabolism of glucose and lipids ([@B77]). SIRT1 is also able to regulate the expression of superoxide dismutase (SOD) and glutathione peroxidase ([@B89]). In addition, since mitochondrial dysfunction leads to the activation of apoptosis, SIRT1 can directly regulate the apoptotic process by modulating acetylation of PGC-1α ([@B114]). SIRT1 also regulates inflammatory response ([@B47]). By modulating the acetylation level of NF-κB p65, SIRT1 is able to control transcription of genes such as IL (interleukin)-1, tumor necrosis factor α (TNF-α), IL-8, IL-6, and other inflammatory factors ([@B77]; [@B76]; [@B107]). Through NF-κB, SIRT1 also regulates the expression of genes such as inhibitor of apoptosis protein (IAP) and B-cell lymphoma-2 (Bcl-2) and tumor necrosis factor receptor (TNFR) ([@B76]).

SIRT1 protects against oxidative stress *via* regulation of FOXO protein acetylation, which is involved in antioxidant processes, apoptosis, and cell proliferation ([@B98]). By activating FOXO/MsSOD pathway, SIRT1 increases the expression of manganese superoxide dismutase (MnSOD) and catalase, counteracting oxidative stress and promoting damage repair ([@B30]). SIRT1 also increases the expression of MnSOD by deacetylating p53, thus enhancing cellular antioxidant capacity ([@B6]; [@B113]; [@B76]).

Over the past few years, the ever-growing awareness that good health goes hand in hand with a healthy and balanced diet has encouraged people to eat more fruit and vegetables, and to take supplements to make up for any deficiency ([@B22]). Bioactive compounds in the diet can act as antioxidant and anti-inflammatory agents, thereby reducing the negative effects of oxidative stress and the incidence of chronic diseases such as obesity, diabetes, and cardiovascular disorders ([@B97]). Several molecules, including natural phytochemical compounds, can modulate SIRT1 activity ([@B65]). Numerous studies have provided evidence of the protective effects of natural polyphenolic substances such as resveratrol, quercetin, curcumin, and fisetin, and of natural non-polyphenolic substances such as berberine ([@B63]). Natural polyphenols are the largest group of phytonutrients and are considered potential agents for the prevention and treatment of stress-related oxidative diseases. They are found in many plants and foods, such as fruits, vegetables, tea, cereals, and wine, and long-term intake is associated with health benefits. Mediterranean diets are in fact linked to a reduced risk of chronic diseases due to the consumption of olive oil and red wine, which contain high amounts of polyphenols ([@B78]).

Most of the evidence supporting the beneficial effects of phytochemical compounds comes from *in vitro* or animal studies, while human studies evaluating the long-term impact of phytomolecules are particularly few or inconsistent. Interventional studies are in fact limited by issues of bioavailability and metabolism. However, *in vitro* studies aimed at identifying cellular targets linked to the beneficial actions of phytonutrient-rich foods at concentrations ranging from nM to µM challenge the translatability of data. After ingestion, these compounds are in fact detected as phase II metabolites and their blood level does not exceed concentrations in the nM range. Substantial amounts of the compounds and their metabolites are degraded in the colon by intestinal microbiota, giving rise to small phenolic acids and aromatic catabolises which are absorbed by the circulatory system ([@B20]). Interesting studies showed that these natural polyphenol and non-polyphenol substances could affect SIRT1 expression/activity ([**Table 1**](#T1){ref-type="table"}) ([@B19]). The main mechanisms of action common to polyphenol and non-polyphenol molecules that lead to antioxidant and anti-inflammatory effects *via* SIRT1 activation are reported in [**Figure 1**](#f1){ref-type="fig"}.

###### 

Classification of nutraceuticals based on their action and food source.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Natural SIRT1 activators   Effect                                                                               Source                                                             References
  -------------------------- ------------------------------------------------------------------------------------ ------------------------------------------------------------------ -----------------------
  Resveratrol                Positive effect on blood lipid profile, antioxidant                                  Dark grapes, raisins, peanuts                                      D'Angelo (2019) \#44\
                                                                                                                                                                                     Zordoky (2015) \#54

  Quercetin                  Anticancer, positive effect on blood lipid profile, antioxidant, anti-inflammatory   Fruits, vegetables, nuts                                           Hung (2015) \#72\
                                                                                                                                                                                     Nabavi (2012) \#68

  Berberine                  Antioxidant, anti-inflammatory                                                       Natural component of traditional Chinese herb *Coptidis rhizoma*   Nabavi (2012) \#68\
                                                                                                                                                                                     Wu (2014) \#70\
                                                                                                                                                                                     Hung (2015) \#72

  Curcumin                   Anticancer, antioxidant, anti-inflammatory                                           Active component in *Curcuma longa*                                Zendedel (2018) \#92

  Fisetin                    Anticancer, cardiovascular preventive, anti-inflammatory, antioxidant                Apples, persimmons, grapes, onions, kiwi, kale, strawberries       Kim (2015) \#98\
                                                                                                                                                                                     [@B15])
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

![Basic mechanisms and effects of SIRT1 activation by polyphenol and non-polyphenol molecules.](fphar-11-01225-g001){#f1}

Here, we focus on the natural molecules resveratrol, quercetin, fisetin, curcumin, and berberine, and elucidate their effect on SIRT1 activation and their potential to treat and/or prevent several human pathologies, mainly associated with metabolic disorders ([**Figure 2**](#f2){ref-type="fig"}).

![Nutraceutical action on SIRT1 expression. Natural substances have beneficial effects on human health by regulating SIRT1 action in different cellular processes ([www.pubchem.ncbi.nlm.nih.gov](www.pubchem.ncbi.nlm.nih.gov)).](fphar-11-01225-g002){#f2}

Natural Compounds Enhancing SIRT1 Expression and Activity {#s2}
=========================================================

Resveratrol {#s2_1}
-----------

Resveratrol (RSV), a non-flavonoid polyphenol found in grapes and grape products such as red wine, exerts an antioxidant action with reported cancer preventive properties ([@B51]). RSV also has anti-inflammatory, anticancer, and anti-neurodegenerative effects ([@B72]). The role of RSV as an immune response modulator was demonstrated in both *in vitro* and *in vivo* studies, where it reversed immune senescence in older rats, reduced inflammatory responses in rodents, and improved immunological activity against cancer cells ([@B62]). RSV was shown to be involved in the activation of macrophages, T cells, and natural killer cells, as well as in the suppression processes of CD4^+^ CD25^+^ regulatory T cells ([@B104]; [@B90]). All these effects are due to its ability to remove ROS, inhibit cyclooxygenase (COX), and trigger anti-inflammatory pathways *via* SIRT1 activation ([@B65]; [@B62]). Activated SIRT1 interrupts TLR4/NF-κB/STAT axis, reduces cytokine production by inactivated immune cells, and inhibits pro-inflammatory factors derived from macrophages/mast cells, such as platelet-activating factor and TNF-α ([@B7]).

RSV-SIRT1 interaction modifies SIRT1 structure and promotes binding activity with its substrates including p65/RelA ([@B106]), a component of the NF-κB complex, which regulates activation of leukocytes and inflammatory cytokines. SIRT1 activated by RSV inhibits acetylation of RelA by reducing the expression of inflammatory factors such as TNF-α, IL-1β, IL-6, metalloprotease (MMP)-1, MMP-3, and NF-κB-mediated Cox-2 ([@B62]). AMP activated protein kinase (AMPK) is also a target of RSV, as it controls SIRT1 activity *via* regulation of cellular levels of NAD^+^, thus acting as an energy sensor ([@B73]). Cyclic adenosine monophosphate (cAMP) levels activate protein kinase A, resulting in phosphorylation and activation of SIRT1 ([@B96]). Activated SIRT1 catalyzes the deacetylation and activation of PGC-1α, thereby promoting beneficial effects in the metabolism ([@B76]).

In different organisms (*S. cerevisiae*, *C. elegans*, and *D. melanogaster*) expressing SIRT1 (or its homologous genes), RSV treatment is able to extend life span. In mammalians, RSV administration can improve SIRT1-dependent cellular processes such as axonal protection ([@B2]), fat mobilization ([@B10]), and inhibition of NF-κB-dependent transcription ([@B107]); these effects are abolished in SIRT1 knockdown models. Numerous studies investigated the beneficial effects of RSV in cardiovascular diseases including hypertension ([@B92]), cardiac ischemia ([@B25]), and atherosclerosis ([@B11]). RSV has an effect on blood vessels, reduces inflammation, and prevents thrombus formation and platelet oxidation ([@B116]). It can also reduce cardiac dysfunction, oxidative stress, fibrosis, and apoptosis in the heart ([@B33]; [@B103]). In addition, RSV was found to improve heart and kidney damage in rats ([@B57]). The protective effect of RSV is associated with an increase in SIRT1 activity, which deacetylates FOXO1 and activates MnSOD downstream. RSV-induced MnSOD also reduces oxidative stress ([@B57]). A recent *in vitro* study showed that RSV reduces hypoxia-induced apoptosis in H9C2 cells through activation of SIRT1/miR-30d-5p/NF-κB axis ([@B36]). RSV treatment decreased cortical and hippocampal malondialdehyde levels while increasing SOD activity and SIRT1 expression in a diabetic rat model ([@B61]).

RSV was shown to activate SIRT1 and improve endothelial function in obese mice *via* upregulation of PPARδ expression/activity in PPARδ mutant mice ([@B12]). It had previously been observed that Akt activation together with PPARδ is involved in vascularization of db/db mice ([@B93]); RSV was subsequently reported to increase phosphorylation of Akt and transcriptional activity of PPARδ in the aorta of wild-type mice, thus supporting the hypothesis of SIRT1-PPARδ interaction, and to strongly decrease LPC-induced mitochondrial ROS in the aortic endothelium of C57BL/6 mice ([@B12]). Taken together, these findings highlight the beneficial effects of RSV against oxidative stress, which is involved in major pathologies such as heart and metabolic disorders. Although RSV is beneficial in many contexts, its pleiotropic actions need to be better studied in order to understand which of its described activities are directly due to SIRT1 modulation and whether this effect is always direct.

Because of the pleiotropic actions of RSV, clinical trials are currently testing its therapeutic potential in a wide range of human diseases. However, of all the mechanisms described in *in vitro* and *in vivo* studies, only a few have been confirmed in humans, such as gene and protein regulation in blood or muscle cells, and Akt signaling pathways ([@B29]; [@B5]). Many clinical studies conducted in healthy patients and volunteers using both high and low doses of RSV highlight its potential cardioprotective benefit through improvement of endothelial function, inflammatory markers, and glucose metabolism. Nevertheless, the mechanisms of action are not yet well defined. Despite clinical evidence of its effects, the poor bioavailability and rapid metabolism of RSV severely limit the potential use of this molecule in the clinic. Future scientific research should focus on identifying actual metabolites or mediators of these observed effects.

To date, 165 clinical trials have tested the efficacy, safety, and pharmacokinetics of RSV in the prevention and treatment of 32 different pathological conditions ([www.clinical.trials.gov](www.clinical.trials.gov)). Restricting the search to interventional phase 1/2/3/4 studies (completed and terminated clinical trials), 55 addressed the ability of RSV to improve the pathological conditions of patients affected by several diseases. Most of these studies tested RSV-mediated effects in central nervous system disorders (Friedreich ataxia, Alzheimer's disease, Parkinson's disease), metabolic disorders \[T2D, insulin resistance, dyslipidemia, hypercholesterolemia, metabolic syndrome X, non-alcoholic fatty liver disease (NAFLD)\]. A phase 1 clinical trial (NCT01640197) tested the effects of chronic resveratrol supplementation (500 mg daily for 28 days) in healthy humans and found considerable improvements in cognitive performance, cerebral blood flow, subjective sleep, mood, health, and blood pressure. A list of completed and terminated clinical trials in which RSV was tested for metabolic disorders is reported in [**Table 2**](#T2){ref-type="table"}. Focusing on completed clinical trials with available results, NCT02114892 evaluated the effect of RSV on metabolic syndrome, demonstrating that, when administered three times per day (1,500 mg/die) before meals, RSV was able to treat and protect from obesity and diabetes with beneficial effects on glucose and lipid metabolism, blood pressure, and body weight. Another phase 1/2 study (NCT02095873) evaluated the effects of a formulation composed of RSV and hesperetin in obese subjects and found that these molecules are dietary inducers of glyxalase 1, improving metabolic and vascular health of obese subjects ([@B102]).

###### 

Resveratrol in clinical trials for metabolic disorders.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Status                   Study Title                                                                                                           Conditions                                                                                                     Intervention                                                                                  Phase       NCT Number
  ------------------------ --------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------- ----------- -------------
  Completed                Effects of Resveratrol in Patients With Type 2 Diabetes                                                               Type 2 Diabetes                                                                                                500 mg to a maximum dose of 3 g daily                                                         Phase 1     NCT01677611

  Terminated               Effect of Administration of Resveratrol on Glycemic Variability in Individuals With Type 2 Diabetes Mellitus          Type 2 Diabetes Mellitus                                                                                       500 mg 3 times daily                                                                          Phase 2     NCT02549924

  Completed                Effect of Resveratrol on Age-related Insulin Resistance and Inflammation in Humans                                    Type 2 Diabetes Mellitus & Insulin Resistance                                                                  1,000 mg twice daily for 28 days                                                              Phase 2     NCT01354977

  Completed                Regulation of Intestinal and Hepatic Lipoprotein Secretion by Resveratrol                                             Dyslipidaemia & Insulin Resistance                                                                             500 mg for 1 week followed by 1 g for 1 week                                                  Phase 2     NCT01451918

  Completed                Effects of Dietary Antioxidants to Prevent Cardiovascular Disease                                                     Hypercholesterolemia & Healthy                                                                                 Dietary Supplement: red wine for 1 month\                                                     Phase 2     NCT02409537
                                                                                                                                                                                                                                                                Dietary Supplement:\                                                                                      
                                                                                                                                                                                                                                                                resveratrol for 1 month                                                                                   

  Completed with results   Healthy Aging Through Functional Food                                                                                 Glucose Intolerance & Aortic Stiffness & Vasodilation                                                          Trans-resveratrol, 90 mg + hesperetin, 120 mg (combination)                                   Phase 1/2   NCT02095873

  Completed                Effects of Resveratrol on Inflammation in Type 2 Diabetic Patients                                                    Type 2 Diabetes Mellitus & Inflammation & Insulin Resistance & Other Disorders of Bone Density and Structure   6 months 40 mg daily then 6 months 500 mg daily                                               Phase 3     NCT02244879

  Completed with results   Effect of Resveratrol Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion                 Metabolic Syndrome X                                                                                           500 mg 3 times daily before meals with a total dose of 1,500 mg daily                         Phase 2     NCT02114892

  Completed                Resveratrol for the Treatment of Non Alcoholic Fatty Liver Disease and Insulin Resistance in Overweight Adolescents   NAFLD & Type 2 Diabetes & Metabolic Syndrome                                                                   75 mg twice daily for a total daily dose of 150 mg for 30 days                                Phase 2/3   NCT02216552

  Completed                A Study of Resveratrol as Treatment for Friedreich Ataxia                                                             Friedreich Ataxia                                                                                              1 g daily (500 mg twice daily) for 12 weeks then 5 g daily (2.5 g twice daily) for 12 weeks   Phase 1/2   NCT01339884

  Completed                Effect of Banaba (Lagerstroemia Speciosa) on Metabolic Syndrome, Insulin Secretion and Insulin Sensitivity            Metabolic Syndrome X                                                                                           Banaba capsules, 500 mg, 2 times daily before meals for 90 days                               Phase 2     NCT02767869
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Quercetin {#s2_2}
---------

The flavonoid polyphenol quercetin (Que; 3,3′,4′,5,7-pentahydroxyflavone) is a natural, safe dietary supplement found in a glycoside form in fruits, vegetables, and nuts, which has antioxidant and anti-inflammatory properties ([@B67]; [@B99]).

In recent years, the scientific community has focused on the potential antiproliferative, chemopreventive and anticarcinogenic activities of Que as well as on its role as a modulator of gene expression. However, Que was also found to have potentially toxic effects including mutagenicity, pro-oxidant activity, mitochondrial toxicity, and inhibition of enzymes involved in hormonal metabolism ([@B55]). Due to its poor solubility, short half-life, and low bioavailability, its medical use is limited ([@B50]). In humans, Que bioavailability is very low (\~ 2%) and absorption varies from 3% to 17% in subjects receiving 100 mg/die ([@B17]). Que may reduce infection ([@B55]), hepatic lipemic-oxidative damage ([@B18]) ([@B112]), and antioxidant risk ([@B101]). In addition, Que is known to exert a modulating action on immunity ([@B26]). As regards its mechanism of action, in some cell lines Que was able to inhibit the production of TNF in macrophages ([@B91]), IL-8 in A549 lung cells induced by lipopolysaccharide (LPS) ([@B27]), and TNF-α and IL-1α mRNA levels in glial cells, causing a decrease in neuronal cell death induced by microglial activation ([@B55]). Mainly in immunity and inflammation, Que acts on leukocytes and targets many intracellular signaling kinases and phosphatases as well as enzymes and membrane proteins ([@B55]). The immunostimulating effect of Que is due to induction of the expression of interferon-γ (IFN-γ) derived from Th-1 and inhibition of IL-4 derived from Th-2 in normal peripheral blood mononuclear cells ([@B68]). In addition, Que reduces T cell proliferation by blocking IL-12-induced tyrosine phosphorylation of JAK2, TYK2, STAT3, and STAT4 ([@B66]; [@B67]). In inflammation, Que inhibits the enzymes COX and lipoxygenase ([@B54]; [@B81]). In the RAW 264.7 cell line, Que was also shown to counteract LPS-induced inflammation by phosphorylation of tyrosine phosphatidylinositol-3-kinase (PI3K)-p85 and complex formation of toll-like receptor 4 (TLR4)/MyD88/PI3K ([@B24]).

Oxidative stress occurs following an imbalance of the body's antioxidant defence mechanisms and excessive generation of free radicals, and is involved in various pathologies such as diabetes, atherosclerosis, hypertension, neurodegenerative diseases, inflammation, and cancer ([@B69]). Que is a powerful ROS scavenger and its antioxidant action is due to the presence of two pharmacophores within the molecular structure, which confer a favorable configuration for free radical elimination ([@B17]). Generally, Que reduces the effects of free radicals by transferring the hydrogen atom and stabilizing the radicals, a feature that has a structure-function relationship ([@B69]).

Que can also act as both an antioxidant and pro-oxidant agent. At low concentrations (10--10 µM), Que displayed a protective effect against oxidative DNA damage (*in vitro*) in human lymphocytes ([@B55]). At concentrations between 5 µM and 50 µM, Que was able to directly eliminate ROS *in vitro* ([@B17]). However, its effect *in vivo* is very likely not direct but due to its ability to modulate the cell's antioxidant defense mechanisms; moderate oxidative stress can in fact increase the cell's antioxidant defenses, resulting in general cytoprotection ([@B35]). Recent research showed that oxidized LDL (oxLDL) induces oxidative stress ([@B53]). Oxidative injuries promote ROS generation in human endothelial cells and SIRT1 regulates endothelial function. Therefore, enhancement of SIRT1 activity and SIRT1/AMPK axis upregulation inhibits oxidative injury, inducing endothelial dysfunction ([@B14]) ([@B85]). Que may reduce oxLDL-induced oxidative damage by upregulating SIRT1 and AMPK ([@B42]), therefore potentially preventing oxLDL-impaired SIRT1 inhibition linked to endothelial dysfunction. These findings indicate that SIRT1 can function as a regulator to improve AMPK activity under oxLDL stimulation ([@B42]).

It was very recently shown that Que (70 mg/kg) can reduce insulin resistance and improve glucose metabolism by reducing sensitivity to T2D/insulin resistance in ob/ob mice *via* SIRT1 activation ([@B40]). In this context, another study showed that in streptozotocin-induced diabetic rats, Que (100 mg/kg) inhibits oxidative damage by increasing SIRT1 expression and decreasing levels of NF-κB, a SIRT1 substrate ([@B45]).

In recent years, the scientific community has focused on the role of apoptosis in cardiovascular disease, showing that oxidative stress, myocardial ischemia, hypoxia, and ischemia/reperfusion injury may induce myocardial apoptosis ([@B21]). Tang and colleagues evaluated the effects of Que in improving myocardial ischemia/reperfusion injury (MI/R)-induced cell apoptosis both *in vitro* and *in vivo*. SIRT1 and PGC-1α expression levels were decreased in rat MI/R groups, but were significantly increased after treatment with Que ([@B91]). Furthermore, activation of SIRT1/PGC-1α pathway upregulated Bcl-2 expression and downregulated Bax, exerting anti-apoptotic effects. The authors hypothesized that Que might improve MI/R-induced myocardial damage *via* regulation of SIRT1/PGC-1α and Bcl-2/Bax pathways ([@B91]). Que is also reported to regulate ROS generation and mitigate mitochondrial dysfunction by promoting their biogenesis. Specifically, in a study to develop a therapeutic strategy for osteoarthritis, Que was shown to increase expression levels of SIRT1, PGC-1α, NRF1 and NFR2, TFAM, and phospho-AMPK α in osteoarthritis rats, confirming the hypothesis that Que might act *via* the AMPK/SIRT1 signaling pathway ([@B75]). Overall, these findings suggest that Que may counteract cardiovascular disease and oxidative damage.

The growing body of evidence supporting the beneficial effects of Que has led to its clinical use, as demonstrated by the number of clinical trials (72 studies on ClinicalTrials.gov). A list of completed studies using Que in different metabolic and inflammatory conditions is reported in [**Table 3**](#T3){ref-type="table"}. Specifically, a phase 2 clinical trial (NCT01839344) measured the effect of Que on glucose tolerance and postprandial endothelial function in subjects with T2D compared to the effect of an alpha-glusidase inhibitor, acarbose. The administration of 2 g of Que led to a decrease in postprandial blood glucose (NCT01839344). Given its antioxidative and anti-inflammatory capacities, this flavonoid was considered a good candidate for antioxidant therapy in mucositis (NCT01732393), hepatitis C (NCT01438320), idiopathic pulmonary fibrosis (NCT02874989), osteoporosis (NCT00330096), uric acid metabolism (NCT01881919), cytokine release (NCT01106170), and chronic obstructive pulmonary disease (NCT01708278). In the latter study, Que supplementation was safely tolerated by patients with mild-to-severe chronic obstructive pulmonary disease, opening the way towards the potential use of Que as a therapeutic agent for this condition.

###### 

Quercetin in clinical trials for metabolic and inflammatory disorders.

  Status                   Study Title                                                                                 Conditions                                                                     Intervention                                                                                                             Phase           NCT Number
  ------------------------ ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------ --------------- -------------
  Completed                Effect of Quercetin in Prevention and Treatment of Oral Mucositis                           Chemotherapy Induced Oral Mucositis                                            250 mg daily for 3 weeks                                                                                                 Phase 1/2       NCT01732393
  Completed with results   Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD)             Chronic Obstructive Pulmonary Disease                                          500 to 2,000 mg daily for 1 week                                                                                         Phase 1         NCT01708278
  Completed                Q-Trial in Patients With Hepatitis C                                                        Chronic Hepatitis C                                                            28 days                                                                                                                  Phase 1         NCT01438320
  Completed                Effects of Quercetin on Blood Sugar and Blood Vessel Function in Type 2 Diabetes.           Diabetes Mellitus, Type 2                                                      250 mg; oral single dose of 2000 mg                                                                                      Phase 2         NCT01839344
  Completed                Effect of Quercetin Supplements on Healthy Males: a 4-Week Randomized Cross-Over Trial      Hyperuricemia, Gout, Kidney Calculi, Diabetes, Cardiovascular [D]{.ul}isease   500 mg tablet for 28 days with meal (breakfast preferred.)                                                               Early Phase 1   NCT01881919
  Completed                Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial            Idiopathic Pulmonary Fibrosis (IPF)                                            3 doses administered over 3 consecutive days in 3 consecutive weeks, oral administration of quercetin (1,250 mg daily)   Phase 1         NCT02874989
  Completed                Efficacy of Provex CV Supplement to Reduce Inflammation Cytokines and Blood Pressure        Blood Pressure                                                                 330 mg of Provex CV supplement, by mouth, per day, for 4 weeks                                                           Phase 1         NCT01106170
  Completed                Effects of Hesperidin on Bone Mineral Density and Bone Metabolism of Postmenopausal Women   Osteoporosis, Osteopenia                                                                                                                                                                                Phase 3         NCT00330096

However, as for RSV and nutraceuticals in general, the results of molecular studies on Que obtained from *in vitro* investigations and animal models are often inconsistent with data from clinical trials. Concentration factor (dose and timing of administration) and bioavailability are the two main issues that require further clarification. Additional studies are needed to identify the optimal concentration of Que for it to exert a beneficial effect, for example on insulin sensitivity.

Berberine {#s2_3}
---------

Berberine (BBR) is an isoquinoline alkaloid reported to have analgesic, anticancer, anti-inflammatory, and myocardial protective properties ([@B16]). It was found to exert protective antioxidative effects in different physiologic and pathologic conditions ([@B41]; [@B58]). However, the mechanisms underlying these effects remain unclear. BBR was described as a potential antitumor agent that induces cell cycle arrest in G0/G1 phase, increases Cip/p21 and Kip/p27 protein expression, decreases expression of cyclin D1, D2, and DE, and the cyclin-dependent kinases Cdk2, Cdk4, and Cdk6, promoting apoptosis in HL-60 human leukemia cells ([@B56]). BBR can also deregulate telomerase activity and promote mitochondria-dependent apoptosis in HepG2 human hepatocarcinoma cells through caspase 8 and caspase 3 activation, PARP cleavage induction, increased expression of the pro-apoptotic protein Bax through activation of FOXO transcription factors, and inhibition of Bcl-2 and Bcl-x anti-apoptotic protein expression ([@B43]). BBR was observed to exert an apoptotic effect by inducing ROS production and increasing MAPK and JNK activity of p38 in SW620 human colon carcinoma cells, and by increasing Ca^+^ and cytochrome C release in HSC-3 squamous cells ([@B88]). In addition, BBR inhibits the proliferation of cancer cells through an anti-inflammatory pathway. In oral carcinoma cell lines and in SCC-4 cells, BBR inhibits expression of COX2 and AP-1 bond, decreases prostaglandin E2 (PGE2) production, and suppresses NF-κB, IKK, ERK, and JNK activities. Furthermore, BBR can inhibit colon cancer cell growth by activating retinoid X receptor α (RXRα), which binds RXRα, and promoting β-catenin degradation ([@B79]). However, some studies highlighted the potential ability of BBR to prevent oxidative stress-induced senescence by activating AMPK and restoring NAD^+^ levels ([@B88]).

Initial research revealed a significant role of SIRT1 signaling in mediating the antioxidant effect of BBR in diabetes ([@B71]) and in lipid metabolism ([@B37]). The lipid-lowering activity mediated by co-treatment with BBR and RSV was investigated in mice exposed to a high fat diet ([@B115]). *In vivo* data showed that BBR combined with RSV lowered total cholesterol, triglyceride, and LDL cholesterol levels in mice. These findings were also confirmed *in vitro* with 3T3-L1 adipocytes treated with BBR or RSV alone. Specifically, BBR and RSV co-treatment was able to reduce lipid accumulation more robustly than single treatments. BBR in combination with RSV displayed hypolipidemic effects likely mediated by SIRT1 expression regulation. Moreover, BBR pre-treatment seemed to counteract SIRT1 downregulation ([@B115]).

The antioxidant and anti-inflammatory effects of BBR were also investigated in heart ([@B108]). BBR-mediated SIRT1 activation reduced MI/R injury by affecting oxidative damage and inflammation signaling. Specifically, BBR exerted an antioxidant effect by decreasing the generation of cardiac superoxide and gp91^phox^ expression, and by increasing SOD levels ([@B108]). A previous study had also shown that SIRT1 activation promotes antioxidant molecule production and decreases pro-apoptotic proteins through FOXO1 activation, thus protecting against MI/R lesions ([@B39]).

As well as activating SIRT1, BBR is also able to decrease FOXO1 acetylation, triggering anti-apoptotic signaling pathways *via* Bcl-2 expression, and Bax and caspase-3 downregulation ([@B108]).

A very recent report described the protective effect of BBR against doxorubicin-induced cardiovascular damage ([@B100]). This effect is mediated by SIRT1/p66Shc pathway ([@B80]). Data obtained in a rat model and in rat H9c2 cardiac cells showed that BBR treatment leads to upregulation of SIRT1 and downregulation of p66shc expression both *in vivo* and *in vitro*, resulting in suppression of ROS production, apoptosis, and mitochondrial damage, and improving cardiac dysfunction. This effect did not occur if H9c2 cells were treated with the SIRT1 inhibitor EX-527 ([@B3]), indicating that BBR action was dependent on SIRT1 ([@B100]). Another study investigated the beneficial effect of BBR in an *in vivo* diabetic mouse model and *in vitro* pancreatic beta cell NIT-1 high glucose treated to induced diabetic condition. BBR attenuated oxidative stress by increasing SOD1 levels through activation of SIRT1 and inhibition of miR-106b expression ([@B13]).

These promising results have paved the way towards the clinical use of BBR. A list of clinical studies investigating the beneficial effects of BBR in inflammatory and metabolic diseases is reported in [**Table 4**](#T4){ref-type="table"}. Given the experimental efficacy of the antidiabetic and antidyslipidemia action of BBR, most of the 18 completed or terminated clinical trials focused on these properties. Two clinical trials tested the anti-diabetic effect of BBR in patients with diabetes or diabetes and dyslipidemia (NCT00425009 and NCT00462046). Several clinical studies investigated its effects on hyperlipidemia and hypercholesterolemia and relative disorders. In particular, two phase 4 clinical trials (NCT02422927 and NCT03470376) tested the ability of a nutraceutical combination containing 500 mg BBR to ameliorate inflammation lipid profile and endothelial injury markers in patients with elevated levels of high-sensitivity C-reactive protein and in HIV-infected patients receiving stable antiretroviral therapy. In addition, a phase 2 clinical study (NCT03216811) assessed the efficacy of a nutraceutical compound (3 mg containing fermented red rice) in terms of cholesterol, and endothelial and inflammatory parameters in subjects with hypercholesterolemia and low-to-moderate cardiovascular risk. The findings of a very recent study suggest that BBR may be effective and safe to reduce cardiovascular risk associated with metabolic syndrome ([@B64]).

###### 

Berberine in clinical trials for metabolic and inflammatory disorders.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Status       Study Title                                                                                                                                                                                                    Conditions                                                             Intervention                                       Phase       NCT Number
  ------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------- -------------------------------------------------- ----------- -------------
  Completed    Therapeutic Effects of Berberine in Patients With Type 2 Diabetes                                                                                                                                              Type 2 Diabetes                                                                                                           Phase 1/2   NCT00425009

  Completed    Efficacy and Safety of Berberine in the Treatment of Diabetes With Dyslipidemia                                                                                                                                Diabetes Mellitus, Type 2, Metabolic Syndrome                          1 g daily                                          Phase 3     NCT00462046

  Terminated   The Therapeutic Effects of Statins and Berberine on the Hyperlipemia                                                                                                                                           Dyslipidemias                                                          500 mg twice daily for 8 weeks                     Phase 4     NCT01697735

  Completed    Efficacy and Tolerability of the Nutraceutical Formulation Coleosoma in Dyslipidemic Subjects (Coleosoma)                                                                                                      Dyslipidemias                                                          Coleosoma 500 mg daily for 12 weeks                Phase 2     NCT03027336

  Completed    Combined Effects of Bioactive Compounds in Lipid Profile (ARM-PLUS-LDL)                                                                                                                                        Hyperlipidemia, Low-density-lipoprotein-type, Elevated Triglycerides   One tablet per day during 12 weeks                 Phase 2/3   NCT01562080

  Completed    Long Term Efficacy and Tolerability of a Nutraceutical Combination (Red Yeast Rice, Policosanols and Berberine) in Low-moderate Risk Hypercholesterolemic Patients: a Double-blind, Placebo Controlled Study   Hypercholesterolemia                                                   500 mg daily for 24 weeks                          Phase 4     NCT02078167

  Completed    NUtraceutical TReatment for hYpercholesterolemia in HIV-infected Patients (NU-TRY(HIV))                                                                                                                        Hypercholesterolemia Inflammation Atherosclerosis                      500 mg daily for 3 months                          Phase 4     NCT03470376

  Completed    Nutraceutical Combination in Patients With Low-grade Systemic Inflammation                                                                                                                                     Hypercholesterolemia Inflammation Atherosclerosis                      500 mg for 3 months                                Phase 4     NCT02422927

  Completed    Nutraceutical in Cardiovascular Primary Prevention (NIRVANA)                                                                                                                                                   Hypercholesterolemia                                                   8-week administration of nutraceutical compound\   Phase 2     NCT03216811
                                                                                                                                                                                                                                                                                                     3 mg                                                           
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Curcumin {#s2_4}
--------

Curcumin (Cur) or 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione (diferuloylmethane) is a natural bioactive polyphenol compound mediating a wide spectrum of biological functions. The molecular structure of Cur consists of two aromatic rings containing phenolic O-methoxy groups linked by a carbon bond, which has a β-unsaturated β-diketone fraction ([@B74]). Thousands of years ago, Indians and Chinese described the health-giving effects of this substance, derived from the turmeric plant ([@B33]). Today, Cur is considered a potential agent with antioxidant, anticancer, and anti-inflammatory properties ([@B109]).

As an antioxidant, Cur is able to eliminate ROS and RNS by increasing the expression of antioxidant proteins *via* induction of upstream coding genes such as nuclear factor erythroid 2-related factor 2 (Nrf2), kelch-like ECH-associated protein 1 (Keap1), and antioxidant response element (ARE) ([@B1]). Nrf2 is a transcription factor involved in cellular stress response. Under normal conditions, the cystine-rich zinc Keap1 metalloprotein binds Nrf2 inside the cytoplasm, promoting ubiquitination and consequent proteasomal degradation and preventing Nrf2 nuclear translocation ([@B83]). In contrast, under stress conditions Keap1 activity is inhibited by phosphorylation and free Nrf2 moves to the nucleus, where it binds to ARE in the regulatory regions of cytoprotective proteins and promotes transcription of antioxidant genes such as SOD, glutathione peroxidase (GPx), and GSH, and of phase II detoxifying enzymes such as heme oxygenase-1 (HO-1), glutathione transferases (GST), nicotinamide adenine dinucleotide phosphate (NADPH), and NAD(P)H dehydrogenase \[quinone\] 1 (NQO1) ([@B83]). Cur is able to activate Nrf2/Keap1/ARE signaling pathway by Michael reaction with thiol residues in Keap1, inducing the release and activation of Nrf2 and promoting antioxidant effects ([@B94]; [@B109]).

Cur was also shown to exert immunomodulatory activity by interacting with elements involved in inflammatory response including JAK/STAT pathway, suppressor of cytokine signaling (SOCS) expression, and TLR4/MyD88/NF-κB axis. Cur inhibits phosphorylation of JAK/STAT by binding with its α,β-unsaturated carbonyl portion to residue 259 of cysteine in STAT3 with subsequent activation. It is known that *in vitro*, even at 7.5 µM concentration, Cur is able to phosphorylate STAT3 and attenuate inflammatory response ([@B83]). SOCS is an antagonist of JAK/STAT signaling and is involved in the regulation of inflammatory proteins and cytokines. *In vitro*, Cur restores expression of SOCS1 and SOCS3, and inhibits expression of IL-6, TNF-α, and PGE2 in RAW 264.7 macrophages ([@B31]), while *in vivo* it restores immunological balance by acting on JAK/STAT/SOCS signaling, inhibiting JAK2, STAT3, and STAT6 phosphorylation and increasing SOCS1, SOCS3, and PIAS3 expression ([@B111]). Furthermore, some *in vitro* and *in vivo* studies show that Cur can downregulate TLR4, MyD88, and NF-κB signaling at neuronal level by inducing the release of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), producing an anti-inflammatory effect.

Cur is able to act on apoptosis and on mitochondrial biogenesis and dysfunction through SIRT activation by small molecules ([@B32]). Cur can downregulate expression of growth factor receptors, transcription factors, TNFs, and nitric oxide synthase, and increase AMPK levels. In vascular smooth muscle cells, Cur promotes AMPK activation, which enhances superoxide and ATP production. This event stimulates an increase in NAD^+^ levels and SIRT1 activation ([@B110]). Cur-induced SIRT1 upregulation has beneficial effects against a range of diseases including cardiac fibrosis, diabetes, and ischemia/reperfusion injury ([@B110] \#7; [@B105] \#5). The involvement of mitochondrial oxidative damage in several diseases such as MI/R is well known ([@B105]). Yang and colleagues investigated SIRT1 action after Cur treatment and the manner in which Cur might attenuate MI/R-induced mitochondrial oxidative damage. *In vivo* and *in vitro* experiments on rat heart and cardiomyocytes showed that Cur pre-treatment had protective effects, decreasing myocardial infarct size ([@B105]). Heart injury and mitochondrial oxidative damage are characterized by ROS overproduction and a reduction in succinate dehydrogenase or COX activity, leading to mitochondrial respiratory chain deficiency ([@B105]). Cardiomyocytes treated by Cur displayed upregulation of SIRT1, COX, and succinate dehy-drogenase (SDH), and downregulation of Bax. These effects were abolished when cardiomyocytes were treated with SIRT1 siRNA. In these conditions, the levels of decreased SIRT1 abolished the effects of Cur treatment. These findings show that Cur-induced cardio-protection was mediated by SIRT1 ([@B105]). T2D is a chronic illness requiring continuing care to prevent long-term and acute complications. Cur may have positive effects in T2D by mediating the reduction of NF-κB expression in inflammatory pathway ([@B110]). NF-κB deregulation can influence other mechanisms in which SIRT1 and AMPK are involved, such as glucose absorption in skeletal muscle. Data obtained in diabetic mice models showed that supplementation of Cur for 8 weeks might promote indirect activation of SIRT1 through AMPK ([@B46]).

Over time, preclinical studies have shown that Cur can act in various human diseases including immunodeficiency, virus infections, rheumatoid arthritis, myocardial infarction, atherosclerosis, and diabetes ([@B38]). A phase I study was published for the first time in 2001. Patients were subjected to five different Cur doses (500, 1,000, 2,000, 4,000, and 8,000 mg) every day for 3 months, and data showed that Cur treatment up to 8,000 mg/day is not toxic ([@B38]). Another study investigated Cur-mediated effects in patients with chronic non-alcoholic pancreatitis, showing that patients had a strong reversal of lipid peroxidation ([@B23]). The development of new routes of administration and new formulations of Cur with better bioavailability could be fundamental for future therapeutic strategies.

A list of completed and terminated clinical trials investigating the effects of Cur in metabolic and inflammatory diseases is reported in [**Table 5**](#T5){ref-type="table"}. A phase 2 clinical study (NCT01925547) investigated the effect of Cur micelles on inflammation and lipid metabolism markers in subjects at risk for metabolic syndrome. Two other trials, a phase 2 (NCT02017353) and a phase 3 (NCT02099890) study, investigated the effect of Cur on inflammation induced by endometrial carcinoma and spinal cord injury, respectively. Interesting results from three phase 2/3 clinical studies showed that Cur (as capsules or gel) prevents or reduces radiation-induced dermatitis in breast cancer patients receiving radiotherapy, enhancing the function of normal tissues (NCT01246973, NCT01042938, NCT02556632).

###### 

Curcumin in clinical trials for metabolic and inflammatory disorders.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Status                   Study Title                                                                                                                          Conditions                                                                Intervention                                              Phase       NCT Number
  ------------------------ ------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------- --------------------------------------------------------- ----------- -------------
  Completed                Micellar Curcumin and Metabolic Syndrome Biomarkers                                                                                  Metabolic Syndrome, Protection Against                                    20 mg of curcumin at the beginning, after 3 and 6 weeks   Phase 2     NCT01925547

  Completed                Effect of Curcumin Addition to Standard Treatment on Tumour-induced Inflammation in Endometrial Carcinoma                            Endometrial Carcinoma                                                     2 g daily for 2 weeks                                     Phase 2     NCT02017353

  Completed                The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury                                        Neuropathic Pain, Depression, Cognitive Impairment                        400 mg\                                                   Phase 3     NCT02099890
                                                                                                                                                                                                                                          Baseline/3 months/6 months                                            

  Completed with results   Oral Curcumin for Radiation Dermatitis                                                                                               Radiation-induced Dermatitis, Breast cancer                               2 g 3 times daily for 1 week                              Phase 2/3   NCT01246973

  Completed with results   Curcumin for the Prevention of Radiation-induced Dermatitis in Breast Cancer Patients                                                                                                                          2 g 3 times daily (\~4--7 weeks)                          Phase 2     NCT01042938

  Completed with results   Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer (Curcumin-II)   Breast Carcinoma, Breast Carcinoma, Pain, Radiation-Induced Dermatitis,                                                             Phase 2     NCT02556632
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Fisetin {#s2_5}
-------

The dietary flavonoid fisetin (3,3′,4,7-tetra-hydroxyflavone) is a natural polyphenol present in plants and fruits such as apples, persimmons, grapes, onions, kiwi, kale, and strawberries, whose daily intake is estimated to be about 0.4 mg ([@B48]). This human diet constituent is reported to exert some beneficial anticancer, cardiovascular preventive, anti-inflammatory, and antioxidant effects that support normal cell homeostasis and cytoprotection ([@B15]; [@B49]). Fisetin was shown to have neuroprotective activity in various Huntington's disease models through ERK activation and to inhibit melanoma growth by suppressing Akt/mTOR1 pathway ([@B82]). A recent study reported that fisetin reduces myocardial tissue damage in a reperfusion ischemia model by suppressing mitochondrial oxidative stress and inhibiting glycogen synthase kinase 3β ([@B84]). As a polyphenol, fisetin can counteract oxidative stress and mediate immune response *via* AMPK/SIRT1 and Nfr2 pathways (see [**Figure 1**](#f1){ref-type="fig"}). Fisetin was shown to increase SIRT1 expression and enhance SIRT1-mediated PPAR and FOXO1 deacetylation in 3T3L1 cells ([@B49]). Specifically, fisetin enhanced the association between SIRT1 and the PPARγ promoter, leading to a block of its transcriptional activity, adipogenesis, and lipid accumulation ([@B49]). Lipid accumulation is a common feature in NAFLD ([@B60]). Increased fatty acid synthesis and hepatocyte accumulation is associated with metabolic disorder ([@B60]). Fisetin treatment in NAFLD mice reduced epididymal adipose tissue, hepatocyte steatosis, and fatty acid synthesis. The data reported by Liou et al. showed an increase in AMPKα phosphorylation and SIRT1 expression levels, while *in vitro* results revealed a reduction in lipid accumulation and an increase in lipolysis. The beneficial effects of fisetin were also linked to its action as a caloric restriction mimetic (CRM) ([@B86]). Natural compounds such as metformin and resveratrol display the ability to mimic the effects of caloric restriction, acting on stress response and metabolic pathways ([@B44]). A recent study investigated the neuroprotective effects of fisetin as a possible CRM against apoptosis, oxidative stress, aging, and neurodegeneration ([@B86]). The authors showed that aging of rat brain induced an increase in pro-inflammatory cytokines and that treatment with CRMs such as metformin can reduce inflammation ([@B87]). In an attempt to demonstrate that fisetin could have beneficial effects against neuro-inflammation comparable to metformin, Singh et al. showed that fisetin mediated protective effects *via* SIRT1 activation, enhancing NF-κB deacetylation and promoting inhibition of pro-inflammatory gene expression ([@B87]). Data suggested that fisetin may be a suitable therapeutic candidate for aging and neurological diseases.

However, there are only six currently available clinical trials using fisetin, most of which are still recruiting ([**Table 6**](#T6){ref-type="table"}). These pilot studies aim to test the anti-inflammatory efficacy of fisetin in Frail Elderly Syndrome (NCT03675724 and NCT03430037) and in symptomatic knee osteoarthritis patients (NCT04210986). Another phase 2 clinical study (NCT03325322) intends to evaluate the effects of oral fisetin on adipose tissue-derived mesenchymal stem/stromal cell function, kidney function, inflammation, and physical function in subjects with chronic kidney diseases and diabetes.

###### 

Fisetin in clinical trials for inflammatory disorders.

  Status       Study Title                                                                                           Conditions                                                           Intervention                                                                             Phase       NCT Number
  ------------ ----------------------------------------------------------------------------------------------------- -------------------------------------------------------------------- ---------------------------------------------------------------------------------------- ----------- -------------
  Recruiting   Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults                 Frail Elderly Syndrome                                               20 mg/kg daily orally for 2 consecutive days                                             Phase 2     NCT03675724
  Recruiting   Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women                  Frail Elderly Syndrome                                               20 mg/kg daily orally for 2 consecutive days, for 2 consecutive months.                  Phase 2     NCT03430037
  Recruiting   Senolytic Drugs Attenuate Osteoarthritis-Related Articular Cartilage Degeneration: A Clinical Trial   Osteoarthritis, Knee                                                 20 mg/kg for 2 consecutive days, followed by 28 days off, then 2 more consecutive days   Phase 1/2   NCT04210986
  Recruiting   Inflammation and Stem Cells in Diabetic and Chronic Kidney Disease                                    Chronic Kidney Diseases, Diabetes Mellitus, Diabetic Nephropathies   20 mg/kg daily orally for 2 consecutive days                                             Phase 2     NCT03325322

Conclusions {#s3}
===========

*In vitro* and *in vivo* studies as well as clinical trials in humans show that SIRT-activating compounds derived from natural sources could preserve human health and might prove beneficial for the prevention and treatment of a plethora of human diseases. The fact that many of these natural molecules are introduced through diet underscores the importance of dietary intervention to correct predisposition and life-style disorders. However, it remains unclear whether (or not) the effects of these compounds are mostly related to SIRT activation and what drug dose/concentration is required. Since most of the natural compounds described here exhibit pleiotropic effects, determining a direct link between SIRT activation and improvement in human health is very challenging. It is also evident that a more robust correlation between health effects and administration of the bioactive compounds needs to be established in order to understand their biological impact and their direct association with SIRT activation. An additional issue is that, although numerous studies have been carried out, the majority only address the role of SIRT1 and its pharmacological regulation. Our current knowledge of the potential pharmacological activation of the expression/activity of other SIRTs is largely incomplete. A greater insight into the selectivity and specificity of natural SIRT activators may help understand the myriad beneficial effects described to date. A further question is related to the cell/context-specific expression of some SIRTs, cofactor availability, and context-specific action of some of the described modulators. Further investigations will be required to provide a more detailed understanding. In addition, some natural SIRT modulators, such as Cur, display poor bioavailability and solubility. Treatment with higher bioavailable preparations of Cur derivatives may result in increased SIRT1-activating action, further substantiating the link between SIRT1, Cur, and therapeutic effects. The fact that studies indicate that the majority of SIRT activators (or at least SIRT1-targeting activators) exert both direct activating effects and indirect effects *via* modulation of SIRT1 downstream pathways complicates the interpretation of results and, particularly, the mining of data specifically dependent on direct SIRT1 binding and activation. Similarly, the activating effects resulting from SIRT1 binding are reported to be either dependent on the catalytic domain or related to different domains, leaving considerable uncertainty as to the activating binding mode and its context specificity upon drug response. Despite the generally encouraging data from *in vitro* and *in vivo* studies, supporting molecular evidence providing clues to these unanswered questions is still lacking. A better understanding of the molecular mechanisms of these natural molecules (or their derivatives) may lead to further and more focused development of their preclinical and clinical use.
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